Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer

This study is currently recruiting participants.
Verified April 2014 by Hoosier Oncology Group
Sponsor:
Collaborator:
OncoGenex Technologies
Information provided by (Responsible Party):
Hoosier Oncology Group
ClinicalTrials.gov Identifier:
NCT01780545
First received: January 25, 2013
Last updated: April 14, 2014
Last verified: April 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: July 2016
  Estimated Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)